Analyst Activity – Piper Jaffray Companies Raises Its Price Target On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to

ME Staff
-
0

Analyst Ratings For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Today, Piper Jaffray Companies raised its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to per share.

There are 4 hold ratings, 20 buy ratings on the stock.

The current consensus rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is Buy (Score: 2.83) with a consensus target price of $127.20 per share, a potential 3.75% downside.

Some recent analyst ratings include

  • 7/19/2017-Jefferies Group LLC Reiterated Rating of Buy.
  • 7/19/2017-HC Wainwright Reiterated Rating of Hold.
  • 7/19/2017-Janney Montgomery Scott Upgrade from a “Neutral ” rating to a ” Buy” rating.
  • 7/19/2017-Cowen and Company Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 7/19/2017-Barclays PLC Upgrade from a “Equal Weight ” rating to a ” Overweight” rating.

Recent Insider Trading Activity For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has insider ownership of 1.80% and institutional ownership of 94.08%.

  • On 7/3/2017 Jeffrey Chodakewitz, CMO, sold 3,438 with an average share price of $127.80 per share and the total transaction amounting to $439,376.40. View SEC Filing
  • On 6/21/2017 Jeffrey Chodakewitz, CMO, sold 5,157 with an average share price of $132.87 per share and the total transaction amounting to $685,210.59. View SEC Filing
  • On 6/21/2017 Paul M Silva, SVP, sold 2,577 with an average share price of $133.36 per share and the total transaction amounting to $343,668.72. View SEC Filing
  • On 6/5/2017 David Altshuler, EVP, sold 7,500 with an average share price of $130.00 per share and the total transaction amounting to $975,000.00. View SEC Filing
  • On 6/2/2017 Jeffrey M Leiden, CEO, sold 147,101 with an average share price of $129.50 per share and the total transaction amounting to $19,049,579.50. View SEC Filing
  • On 6/2/2017 Sangeeta N Bhatia, Director, sold 1,176 with an average share price of $128.44 per share and the total transaction amounting to $151,045.44. View SEC Filing
  • On 6/2/2017 Stuart A Arbuckle, EVP, sold 70,969 with an average share price of $128.06 per share and the total transaction amounting to $9,088,290.14. View SEC Filing

Recent Trading Activity for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Shares of Vertex Pharmaceuticals Incorporated closed the previous trading session at 132.16 up +2.95 2.28% with 3,311,555 shares trading hands.